CD38 Exacerbates Focal Cytokine Production, Postischemic Inflammation and Brain Injury after Focal Cerebral Ischemia by Choe, Chi-un et al.
CD38 Exacerbates Focal Cytokine Production,













1Department of Neurology, University Hospital Hamburg-Eppendorf, Hamburg, Germany, 2Department of Immunology, University Hospital Hamburg-Eppendorf,
Hamburg, Germany, 3Department of Clinical Chemistry, University Hospital Hamburg-Eppendorf, Hamburg, Germany
Abstract
Background: Converging evidence suggests that inflammatory processes significantly influence brain injury and clinical
impairment in ischemic stroke. Although early studies suggested a key role of lymphocytes, recent data has emphasized the
orchestrating function of innate immunity, i.e., macrophages and microglia. The bifunctional receptor and ectoenzyme
CD38 synthesizes calcium-mobilizing second messengers (e.g., cyclic ADP-ribose), which have been shown to be necessary
for activation and migration of myeloid immune cells. Therefore, we investigated the dynamics of CD38 in stroke and the
impact of CD38-deficiency on cytokine production, inflammation and cerebral damage in a mouse model of cerebral
ischemia-reperfusion.
Methodology/Principal Findings: We show that the local expression of the chemokine MCP-1 was attenuated in CD38-
deficient mice compared with wildtype mice after focal cerebral ischemia and reperfusion. In contrast, no significant
induction of MCP-1 expression was observed in peripheral blood after 6 hours. Flow cytometry analysis revealed less
infiltrating macrophages and lymphocytes in the ischemic hemisphere of CD38-deficient mice, whereas the amount of
resident microglia was unaltered. An up-regulation of CD38 expression was observed in macrophages and CD8
+ cells after
focal cerebral ischemia in wildtype mice, whereas CD38 expression was unchanged in microglia. Finally, we demonstrate
that CD38-deficiency decreases the cerebral ischemic injury and the persistent neurological deficit after three days of
reperfusion in this murine temporary middle cerebral artery occlusion (tMCAO) model.
Conclusion/Significance: CD38 is differentially regulated following stroke and its deficiency attenuates the postischemic
chemokine production, the immune cell infiltration and the cerebral injury after temporary ischemia and reperfusion.
Therefore CD38 might prove a therapeutic target in ischemic stroke.
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Introduction
Inflammation plays an important role in infections to fight
pathogens, but can be detrimental in autoimmune diseases and
ischemia-reperfusion injury. In stroke, inflammatory cascades are
triggered by cerebral ischemia-reperfusion and considerably
influence secondary brain injury due to cytotoxic neuronal cell
death [1]. The activation, migration and accumulation of
immune cells characterize crucial steps of postischemic inflam-
mation and are mediated by extracellular cytokines (e.g.
chemokines) as well as intracellular molecular signals (e.g. second
messengers) [2]. Although different chemokines and receptors,
like monocyte chemotactic protein-1 (MCP-1 or CCL2) and
CCR2, are involved in immune cell activation and chemotaxis
after stroke, an approach aiming at multiple targets remains to be
proven [3,4].
The bifunctional ectoenzyme and receptor CD38 represents
such a versatile modulator regulating the migration of neutrophils
and dendritic cells in response to different chemokines, like CCL2,
CCL19, CCL21, CXCL12, as well as to bacterial-derived
chemoattractants, like N-formyl-methione-leucine-phenylalanine
(fMLF) [5,6,7,8]. CD38, which is widely expressed on hemato-
poetic as well as non-hematopoetic cells, catalyzes the production
of second messengers (i.e cyclic adenosine dinucleotide phosphor-
ibose (cADPR), adenosine dinucleotide phosphoribose (ADPR),
nicotinic acid adenine dinucleotide phosphate (NAADP)), which
act as potent intracellular calcium mobilizing agents [5,6,7,8]. In
addition to its enzymatic function, CD38 has been suggested to act
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adhesion and rolling of lymphocytes. These functions of CD38 as
ectoenzyme and receptor have been implicated to mediate the
humoral and innate immune response of lymphoid and myeloid
lineage cells [5,9]. Especially, the priming of T-cells as well as the
directional migration of myeloid lineage cells seem to depend on
CD38 and its products ADPR and cADPR [5,10].
Just recently modulation of mainly detrimental inflammatory
processes have been attributed to hematopoetic cells like
lymphocytes and macrophages, which are the primary source for
pro-inflammatory cytokines like IL-17 and IL-23, respectively
[11,12]. Therefore, the infiltration of the ischemic brain by
hematopoetic immune cells marks an essential step of postischemic
inflammation. CD38-deficiency has been demonstrated to impair
migration of hematopoetic myeloid cells and to attenuate
lymphocyte activation. To determine the functional significance
of CD38 in ischemic stroke, we compared local and systemic
cytokine and chemokine levels, the amount of infiltrating
inflammatory cells, the CD38 expression pattern of leukocyte




C57BL/6 mice and GFP transgenic mice (TgN(TIE2GFP)
287Sato/J in FVB/N/J background) were obtained from the
Jackson Laboratory (Bar Harbor, ME). CD38
2/2 mice were
backcrossed onto the C57BL/6 background for 12 generations as
described previously [5]. All animal experiments have been
conducted according to relevant national and international
guidelines (German Animal Welfare Act) and have been approved
by the local Animal Care and Use Committee (Behoerde fuer
Soziales, Familie, Gesundheit und Verbraucherschutz - Lebens-
mittelsicherheit und Veterinaerwesen – animal permit number
G08/014_CD38).
Temporary Middle Cerebral Artery Occlusion (tMCAO)
C57BL/6 male mice (12–15 weeks) were used in accordance
with the Guide for the Care and Use of Laboratory Animals and
approved by the Institutional Animal Care and Use. Briefly, mice
were anesthetized (isoflurane 1–2% v/v oxygen) and analgesized
(buprenorphine 0.03 mg/kg b.w. i.p. every 12 h for 24 h). As
previously described, tMCAO was achieved by using the
intraluminal filament method (6–0 nylon) for one hour [13,14].
Exemplary mice were monitored using transcranial temporal laser
Doppler and every mouse was scored on a scale from 0–5 (0 no
deficit, 1 preferential turning, 2 circling, 3 longitudinal rolling, 4
no movement, 5 death) after reawakening and daily until sacrifice.
Mice were sacrificed at indicated time points after reperfusion
using isoflurane and decapitation. To measure the infarct volume,
brains were removed after MCAO and evaluated using 2,3,5-
triphenyltetrazolium chloride staining of 1 mm thick brain slices.
All analyzed infarcts involved cortical tissue. The surgical
procedure and the analysis were conducted in a blinded fashion.
The stained sections were scanned (2.400 dpi), the digitized
images of each brain section and the infarct area were quantified
using a computerized image analysis program (Image J, USA).
Bone Marrow Transplantation
Bone marrow chimeric mice were created as described
previously (Cassiani-Ingoni et al., 2007). In brief, 6 weeks old
male congenic C57BL/6J-recipients (20–30 g) were sublethally
irradiated with 6.5 Gy. Bone marrow was obtained by flushing the
femur bones from male donor GFP-transgenic animals (C57BL/
6J) with sterile phosphate buffered saline. Bone marrow cells were
suspended in the same buffer, washed several times, counted and
injected into the tail vein at 1610
7 cells/recipient. Animals with
more than 90% CD45
+ GFP
+ leukocytes verified by peripheral
blood analysis were used for further experiments 6 weeks after
transplantation.
Mouse Brain Extracts
Animals were euthanized 6 or 24 hours postreperfusion and
brains were directly prepared in cold PBS. Hemispheres were
separately homogenised mechanically in homogenisation buffer
(140 mM NaCl; 20 mM Tris-HCl pH 7,6; 5 mM EDTA; 16
complete protease inhibitors) and extracts additionally sonicated
for 30 s. Resulting extracts were centrifuged (6000 rpm) for
10 min at 4uC. Supernatants were further centrifuged
(14000 rpm) for 10 min at 4uC and final supernatants used for
ELISA analysis.
Cytokine Production (ELISA)
For quantitative determination of MCP-1, TNF-a and IFN-c
protein level in serum or brain extracts, standard ELISA was
performed according to the manufacturer’s instructions (ELISA
Set, OptEIA
TM, BD Biosciences, Heidelberg, Germany). Optical
density at 450 nm was obtained using the Tecan Sunrise
TM and
Magellan
TM system (Maennedorf, Austria) and protein concen-
trations were determined using a provided standard curve.
Fluorescence-Activated Cell Sorter (FACS) Analysis
As previously described, animals were euthanized and perfused
with PBS [14]. Brains were dissected, cerebella removed, and
hemispheres divided into left ischemic (ipsilesional) or right
nonischemic (contralesional). Three to 4 hemispheres were pooled,
incubated for 30 minutes at 37uC (1 mg/ml collagenase, 0.1 mg/
ml DNAse I in DMEM), and pressed through a cell strainer
(40 mm; BD Biosciences, Heidelberg, Germany). Next, cells were
incubated with standard erythrocyte lysis buffer on ice, separated
from myelin and debris by Percoll gradient (GE Healthcare;
1095 g/ml and 1030 g/ml) centrifugation, and incubated with
appropriate antibody cocktails as previously described [14]
(30 minutes, room temperature) in fluorescence-activated cell
sorter buffer (0.5% bovine serum albumin, 0.02% sodium azide
in phosphatebuffered saline). For TrueCount (Becton Dickinson)
fluorescence bead absolute quantification, 10% of cells were
quantified according to the protocol on the basis of CD45-positive
events. For CD38 expression cells were labelled with anti-mouse
fluorochrome-conjugated antibodies (BD Biosciences): CD38-PE
(1:300), CD11b-FITC (1:300), CD11c-APC (1:300), CD45-PE-
Cy7 (1:150), CD8-Pacific Blue (1:300) and CD4-APC-Cy7 (1:150)
and were distinguished as previously described (figure S1) [14]
Cells were analyzed by blinded evaluators using a LSR II (BD
Biosciences) and FACS Diva software (BD Biosciences). Up to
2 000 000 forward light scatter events per tube were acquired.
Immunohistochemistry
Mice were anesthetized with isoflurane inhalant and perfused
through the left ventricle using 10ml PBS followed by 50ml of ice-
cold 4% PFA. The brains were post-fixed in 4% PFA overnight at
4uC followed by cryoprotection in 30% sucrose (w/v) in PBS until
the brains sank to the bottom of the solution. After snap freezing of
the embedded brains in isopentane pre-cooled with liquid
nitrogen, brains were cut into 6 mm frontal sections using a Leica
CM3050. Sections were then exposed to PBS containing 0.3%
CD38 Exacerbates Ischemic Stroke and Inflammation
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antibody binding for a minimum of 60 min, followed by
incubation with the primary antibodies and lectins at 4uC
overnight (CD11b, 1:100, BD Pharmingen; GFAP, 1:1000,
DAKO; isolectin GS IB4 Alexa Fluor 488, 1:500, Invitrogen).
Sections were then incubated with the appropriate secondary
antibodies (Alexa Fluor 546 goat anti-rat IgG, Alexa Fluor 647
Goat Anti-Rabbit, Invitrogen) at room temperature for 1h, and
counterstained with DAPI (1:1000, Invitrogen). Negative control
sections from each animal were obtained by omitting primary
antibodies. Stained sections were examined with a Leica
DM5000B microscope.
Statistical Analyses
Data in text and figures are mean 6 SEM for the indicated
number (n) of animals or cultures. Statistical comparisons were
made by student’s t-test for infarct size, neurological score and
FACS-analysis. Significance was set at p,0.05. All statistical
analyses were performed using GraphPad Prism software
(GraphPad Software, Inc.).
Results
Cytokine and Chemokine Levels After tMCAO
We used the tMCAO model to explore the role of CD38 in
postischemic chemoattraction. Focal cerebral ischemia was
induced for one hour with the intraluminal filament technique
in wildtype and CD38
2/2 animals. The initial neurological
impairment did not differ between genotypes indicating a similar
brain lesion. Six and 24 hours after tMCAO, the ipsilateral
hemispheres were prepared and protein lysates were analysed for
cytokines with ELISA. Both, wildtype and CD38
2/2 displayed
increased levels of MCP-1, but the increase was significantly lower
in CD38
2/2 mice at 6 and 24 hours after tMCAO compared with
wildtype mice (wildtype vs CD38
2/2 3,460,4 vs 1,560,3 at 6h
and 5,560,7 vs 2,760,9 at 24h, n=5–7, p,0.05, figure 1A), while
TNF-a and IFN-c concentrations in the brain were unaltered
throughout this time period (wildtype vs CD38
2/2 for TNF-a
1,060,04 vs 0,960,04 at 6h and 0,660,01 vs 0,860,1 at 24h,
n=5–8; for INF-c 0,960,03 vs 1,160,1 at 6h and 0,760,04 vs
0,960,2 at 24h, n=5–8, p.0.05, figure 1B, C). MCP-1 levels
were strongly increased also in peripheral blood of wildtype and
CD38
2/2 mice, albeit to similar extents at six hours after tMCAO
(wildtype vs CD38
2/2 7,962,1 vs 5,861,0 at 6h and 0,660,1 vs
1,860,2 at 24h, n=5–8, p.0.05, figure 1D). Twenty-four hours
after tMCAO, MCP-1 levels in peripheral blood were even higher
in CD38
2/2 mice compared with wildtype animals (p,0.01,
figure 1D).
Postischemic Inflammatory Response
Focal chemokine production differentially influences direc-
tional migration of hematopoetic inflammatory cells. MCP-1
Figure 1. CD38
2/2 mice produce less chemokine MCP-1 after tMCAO than wildytpe mice. Ipsilateral hemispheres were lysed 6 or 24 hours
after tMCAO and concentrations of MCP-1, TNF-a and IFN-c were determined by ELISA. Results are represented as increase in cytokine levels relative
to sham-operated control animals. Control values of wildtype and CD38
2/2 mice did not differ significantly from each other (A). In CD38
2/2 mice
levels of MCP-1 increased to a lesser extend than in wildtype mice after 6 and 24 hours reperfusion, whereas cytokine levels of TNF-a and IFN-c
stayed unaltered (B, C). MCP-1 concentrations in peripheral blood (D) did not differ after 6 hours (n=5–8; *p,0.05; **p,0.01; ***p,0.001 versus
control assessed by one-sample t-test).
doi:10.1371/journal.pone.0019046.g001
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which attracts immune cells of myeloid origin, especially
monocytes to the tissue with MCP-1 accumulation. Therefore,
immune cell subtypes invading the ischemic hemisphere were
characterized by FACS-analysis after one hour of middle cerebral
artery occlusion and three days of reperfusion (figure S1). Whilst
the accumulation of CD3
+ cells and macrophages in the ischemic
hemisphere was significantly decreased in CD38
2/2 compared
with wildtype mice (wildtype vs CD38
2/2:C D 3
+ cells 12756215
vs 6386127 and macrophages 2978268196 vs 520062541,
n=3 experiments with 3–4 animals each, p,0.05, figure 2A, B),
the amount of microglia did not differ significantly (wildtype vs
CD38
2/2: 6718961160 vs 5264861462, n=3 experiments with
3–4 animals each, p.0.05, figure 2C). Results from FACS-
experiments corresponded well to immunohistochemical studies,
which revealed smaller infarct sizes after staining for GFAP and
reduced amounts of macrophages, which were distinguished by
positive staining for CD11b and isolectin as well as cell
morphology (figure S2).
In order to distinguish between hematopoetic and local immune
cells, we used GFP bone marrow chimera. Irradiated wildtype
mice reconstituted with GFP positive bone marrow cells were
subjected 6 weeks after transplantation to one hour of tMCAO
and three days of reperfusion. Immune cell subtypes localized in
the ischemic hemisphere were discriminated by FACS-analysis
(figure S3). Macrophages (dark grey) and myeloid dendritic cells
(light grey) highly expressed GFP and therefore originated from
the bone marrow. In contrast, resident microglia were GFP
negative (black).
CD38 Expression of Immune Cells
Upon activation, mature lymphocytes and microglia have been
demonstrated to up-regulate CD38 expression [15,16]. Further-
more, CD38 is known to orchestrate the migration of myeloid
immune cells and modulate the cytokine production of lympho-
cytes [16,17]). Therefore, we analyzed CD38 expression on
immune cells accumulating in the ischemic brain 3, 24 and
72 hours after focal cerebral ischemia induction in CD38
2/2 and




+ cells and CD38
high myeloid dendritic cells did not change
significantly during the observed reperfusion period (p.0.05,
figure 3). In contrast, the subpopulation of CD38
high macrophages
increased from 1362.8% three hours after tMCAO to 3863.5%
twenty-four hours after tMCAO, but normalized to 2164.8%
already 72 hours after tMCAO (3 hours vs 24 hours, p,0.01;
24 hours vs 72 hours, p,0.05; 3 hours vs 72 hours p.0.05;
Figure 2. CD38 modulates cerebral postischemic immune cell infiltration. Infiltrating immune cells were isolated after tMCAO from wildtype
and CD38
2/2 brains and subdifferentiated by multi-color flow cytometry. Significantly less CD3
+ cells and macrophages were found in the ischemic
hemisphere of CD38
2/2 mice (A, B), whereas the number of microglia was unaltered (C) (n=5–6, *p,0.05). The amount of immune cells, i.e. CD3
+
cells, macrophages and microglia, did not change in the contralateral control hemisphere (n=5–6; p.0.05).
doi:10.1371/journal.pone.0019046.g002
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high CD8
+
cells increased from 3564.6% three hours after tMCAO to
6964.6% twenty-four hours after tMCAO and normalized to
24.966.8% three days after focal cerebral ischemia (3 hours vs
24 hours, p,0.01; 24 hours vs 72 hours, p,0.01; 3 hours vs
72 hours p.0.05; figure 3B).
CD38 Increases Focal Ischemic Injury After Transient
Middle Cerebral Artery Occlusion
Finally, focal ischemic infarct size was analyzed after tMCAO
for one hour with the intraluminal filament technique in wildtype
and CD38
2/2 animals. Coronal sections were collected after a 3-
day reperfusion period and stained with 2,3,5-triphenyltetrazolium
chloride. The ischemic area in CD38
2/2 mice was significantly
decreased to 12.864% of hemisphere as compared to 37.067% of
hemispheric volume in control mice (figure 4A). One hour after
MCAO, neurological scores were comparable (control 2.460.4,
n=5; CD38
2/2 2.160.1, n=7, figure 4B). After three days
CD38
2/2 mice showed only minimal neurological deficit, while
neurological impairment was significantly increased in control
mice (control 1.460.4, n=5; CD382/2 0.160.1, n=7,
figure 4C).
Figure 3. Infiltrating immune cells express CD38. Immune cells infiltrating the ischemic brain of wildtype mice were isolated after tMCAO and
subpopulations were analysed by multi-color flow cytometry. The amount of CD38
+ expressing CD8
+ cells (left) and macrophages (middle)
significantly increases 24 hours after tMCAO, whereas the subpopulation of CD38
+ microglia (right) stays unaltered (A). After 72 hours, the number of
CD38
+ CD8
+ cells and CD38
+ macrophages decreased to 3 hour values (n=3–4 in each group; *p,0.05 and **p,0.01).
doi:10.1371/journal.pone.0019046.g003
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Increasing evidence indicates that the postischemic inflamma-
tory response might play a detrimental role in the secondary
progression of stroke injury [2]. Immune-deficient animal models
revealed an amelioration of cerebral ischemic-reperfusion injury
[12,18,19]. The inflammatory infiltrates and its mainly cytotoxic
processes after cerebral ischemia seem to be local and contained to
the penumbral region [14]. Therefore, the recruitment and
accumulation of leukocytes play pivotal roles in initiating and
mediating the cerebral inflammation. Our current work suggests
that CD38 influences immune cell migration as well as activation,
which are both required for the mainly detrimental postischemic
inflammatory response contributing to secondary brain damage.
In CD38-deficient mice, the accumulation of T-cells and
especially macrophages was decreased whereas the amount of
microglia did not differ significantly (figure 2). Two mechanisms
could be accounted for this - i.e. impaired chemokinesis and/or
decreased chemoattraction. Especially, the chemotaxis of myeloid
immune cells, like myeloid dendritic cells and neutrophils, highly
depends on CD38 and its products ADPR and cADPR [9,10].
Therefore, it is not surprising that CD38
2/2 mice show a twenty
fold lower number of infiltrating macrophages than wildtype mice,
but only a three fold lower numbers of infiltrating T-cells (figure 2A
and B). Experiments with GFP
+ bone marrow chimera confirm
previous observations, macrophages and myeloid dendritic cells
found in the ischemic hemisphere, originate in the bone marrow,
while microglia are resident and evolve independent of bone
marrow stem cells (figure S2). Therefore, CD38 differentially
influences the migration of hematopoetic myeloid immune cells.
In addition to an impaired migratory potential, a weaker
induction of local MCP-1 production was observed in CD38
2/2
than in wildtype mice after stroke, despite a similar initial ischemic
brain damage indicated by comparable neurological impairment
and similar elevations of MCP-1 levels in peripheral blood 6 h
after tMCAO illustrating adequate systemic immune responses.
Furthermore, unaltered levels of TNF-a and INF-c in the ischemic
hemisphere demonstrate a distinct attenuation of MCP-1
expression after stroke (figure 1). Among all pro-inflammatory
chemokines, MCP-1 dependent migration is known to strongly
rely on CD38 as well as its products ADPR and cADPR [10].
Importantly, the interaction of MCP-1 with its receptor CCR2 has
been attributed a central role in experimental cardiac, renal and
cerebral ischemia-reperfusion models [20]. After focal cerebral
ischemia an early and local production of MCP-1 was described in
rat, mouse and human patients [21,22,23,24]. Previous studies
have shown that genetic ablation of MCP-1 or its receptor CCR2
resulted in reduced cerebral injury closely related with an
attenuated accumulation of monocytes and macrophages after
stroke [3,4]. In contrast, focal MCP-1 overexpression in brain
Figure 4. CD38-deficiency protects from ischemic stroke and ameliorates clinical impairment after tMCAO. Coronal sections of
representative mouse brains were prepared 3 days after tMCAO from wildtype and CD38
2/2 mice. Vital tissue stains red after treatment with TTC.
Infarct size of CD38
2/2 mice was significantly decreased compared to wildtype mice (A). Corresponding to the cerebral infarct size, neurological
scores in CD38
2/2 mice were significantly lower three days after tMCAO compared to wildtype indicating an attenuated clinical impairment (B)
(n=5–7; *p,0.05 versus).
doi:10.1371/journal.pone.0019046.g004
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increased local transmigration and perivascular accumulation of
macrophages after ischemic stroke [25]. Nonetheless, decreased
MCP-1 production will attenuate attraction and recruitment of
monocytes and myeloid dendritic cells and subsequently amelio-
rate the post-ischemic inflammatory response. Possibly, macro-
phages are necessary to sustain this mainly detrimental immune
reaction, because macrophages themselves represent a significant
source for pro-inflammatory cytokines and chemokines, like MCP-
1 [26,27,28]. Furthermore, the accumulation of macrophages can
be observed as early as six hours after tMCAO and corresponds
well with an up-regulation of CD38 and therefore immune cell
activation [14]. In contrast, no significant alteration of CD38
expression was observed in microglia, CD4
+ cells and myeloid
dendritic cells (figure 3). In line with previously published work,
migration, attraction and activation of macrophages are critical
steps for the initiation and preservation of pro-inflammatory
immune processes after focal cerebral ischemia. Our data show
that these processes highly depend on CD38, because macro-
phages strongly up-regulate CD38 upon stroke and highly rely on
CD38 for effective migration into the ischemic brain. Therefore
macrophages could be the key player to orchestrate the CD38-
dependent effects, because they represent one of the earliest cell
populations to infiltrate the ischemic brain, up-regulate CD38
after stroke and are known to be a major source of MCP-1
production. Nevertheless decreased macrophage infiltration could
merely be a consequence of reduced infarct volume. But in this
case, the amount of microglia would also be reduced, because the
inflammation-independent ischemic brain damage would alter the
amount of all immune cell infiltrates proportionally.
In summary, our data suggest that attenuation of postischemic
cerebral inflammatory processes decrease secondary neurotoxic
cell death, decrease infarct size and ameliorate clinical neurolog-
ical impairment. We have shown that CD38 orchestrates the
recruitment and activation of immune cell subpopulations, the
production of pro-inflammatory cytokines and cytotoxic autoim-
mune response after stroke. Therefore, CD38 might prove to be a
therapeutic target to modulate the inflammatory mechanisms after
cerebral ischemia.
Supporting Information
Figure S1 Exemplary gating strategy for infiltrating
immune cells. Gating strategy for a cell subset derived from 3
days postreperfusion ipsilesional stroked hemispheres (A). Popula-
tions were gated back onto initial CD45/SSCplot (B). Yellow
microglia, green neutrophils, red and orange DCs, and macro-
phages, black and purple lymphocytes, and NK cells.
(TIFF)
Figure S2 Macrophage infiltration is attenuated in
CD382/2 compared with wildtype mice. Staining for
GFAP to demarcate the infarct zone reveals reduced infarct sizes
in CD38
2/2 compared with wildtype 3 days after MCAO for one
hour (A, F). Furthermore, the reduced amount of CD11b
+
monocytes (B, C for wildtype, G, H for CD38
2/2) could be
attributed to macrophages, which were distinguished by isolectin
+
staining and morphology (see arrow for microglia morphology; B,
D for wildtype, G, I for CD38
2/2). The overall amount of cells
was similar as visualized by DAPI staining (E, J).
(TIF)
Figure S3 Macrophages and myeloid dendritic cells
infiltrate the ischemic brain, whereas microglia expand
locally. Irradiated wildtype mice reconstituted with GFP positive
bone marrow cells were subjected to 1h tMCAO. After three days
of reperfusion immune cells were isolated and GFP expression of
different subtypes was discriminated by FACS-analysis Macro-
phages (dark grey) and myeloid dendritic cells (light grey) highly
expressed GFP and therefore originated from the reconstituted
bone marrow. In contrast, microglia (black) were resident (n=3
with four animals for each experiment).
(TIF)
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